Browse > Article
http://dx.doi.org/10.13048/jkm.15042

A Case Report of Efficacy of Growth Height and Peak-Luteinizing Hormone Level Suppression on Idiopathic Gonadotropin-Dependent Precocious Puberty Patient Using Herbal Remedy, Aesopjiyoun-tang  

Nam, Se-hion (Aesop Hospital of Korean Medicine)
Lee, Chong-hai (Aesop Hospital of Korean Medicine)
Tang, Yu-wei (Aesop Clinic of Korean Medicine)
Liu, Yuan-sheng (Aesop Clinic of Korean Medicine)
Kim, Ki-chul (Aesop Clinic of Korean Medicine)
Chun, Sang-yeol (Busan Aijoa Clinic of Korean Medicine)
Yeom, Yu-rim (Aesop Naple Clinic of Korean Medicine)
Kim, Hyung chang (Gamchodang-Aesop pibro Clinic of Korean Medicine)
Lee, Myoung-deok (Aesop Hospital of Korean Medicine)
Publication Information
The Journal of Korean Medicine / v.36, no.4, 2015 , pp. 150-155 More about this Journal
Abstract
The purpose of this report is to evaluate effect of Korean medical treatment on idiopathic gonadotropin-dependent precocious puberty (G-DPP) patient received herbal medicine. We administered Aesopjiyoun-tang remedy to idiopathic G-DPP and analyzed the delay effect by hormonal value and radiographs; the height growth effect by measurement of height. After Korean medical treatment, suppression effect to peak-Luteinizing Hormone level (LHL) is 14.39IU/L to 10.9IU/L for 13month, growth effect to height value is 11cm/13month; and change of mean growth velocity (MGV) is 6.08cm/year to 10.06cm/year. The gain in height by treatment is 3.98cm/year. The result suggests Aesopjiyoun-tang can be an effective treatment for G-DPP. Herbal medicine can be used as an alternative treatment in place of the GnRH treatment.
Keywords
Precocious puberty; Herbal medicine; Growth height; Aesopjiyoun-tang; GnRH treatment;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Carel JC, Leger J. Precocious puberty. The New England journal of medicine. 2008;358:2366 77.   DOI
2 Martin R. Early puberty: what is normal and when is treatment indicated. Horm. Res. 2003;60 (suppl3):31-4.   DOI
3 Brown JJ, Warne GL. Growth in precocious puberty. Indian journal of pediatrics. 2006;73:81-88.   DOI
4 Gluckman PD, Hanson MA. Evolution, development and timing of puberty. Trends in endocrinology and metabolism. 2006;17(1):7-12.   DOI
5 Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab. 2002;87:2090-4.   DOI
6 Kim TH, Coe HJ, Kim S, Lee SW, Chae HW, Kim YS, et.,al. Cinical and Endocrinologic Characteristics of Children Referred for Precocious Puberty. Korean J of pediatrics. 2007;12(2):119-26.
7 Styne D, Grumbach M. Puberty: ontogeny, neuroendocri-nology, physiology, and disorders. In: Kronenberg HM, Mel-med S, Polonsky KS, Larsen PR, editors. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders Co. 2008:969-1166.
8 Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol. 2006;254-255:217-20.   DOI
9 Lim YK, Hur KW, Park SY, Suh KS, Chun SY, Lee SJ, et al. A Case Report of Precocious Puberty in a Female Patient : Significant Improvement in Controlling the Sex Hormone Levels. J Pediatr Korean Med. 2014;28(4):64-70.   DOI
10 Kim JE, Yang SJ, Cho SH, Park HM. A report on the effect of jowisengchung-tang in 2 cases of precocious puberty. J Korean obstet gynecol. 2013;26(2):178-187.   DOI
11 Tanner JM, Healy MJR, Goldstein H. Assessment of skeletal maturity and prediction of adult height. Oxford: Elsevier United Kingdom. 2001.
12 Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment. J Clin Endocrinol Metab. 1999;84(6):1973-8.   DOI
13 Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarre-van de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab. 2000;13 Suppl 1:765-72.   DOI
14 Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab. 2002;87(5): 2090-4.   DOI
15 Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008;159:S3-8.   DOI
16 Partsch CJ, Hummelink R, Peter M, Sippell WG, Oostdijk W, Odink RJ, et al. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty influence on growth and predicted adult height. Horm Res. 1993;39:111-7.   DOI
17 Carel JC, Lahlou N, Guazzarotti L, Joubert -Collin M, Roger M, Colle M, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol. 1995;132:669-704.
18 Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the use of gonadotropin releasing hormone analogs in children. Pediatrics. 2009;123:e752-62.   DOI
19 Zhao J, Yu J. Study on clinical application of kangzao-II recipe in treating girl gonadotropin-releasing hormone dependent sexual precocity. Chinese Journal of Integrated Traditional and Western Medicine. 2003;3:182-84.